Diabetes: Novo Nordisk insulin cartridges in short supply in Europe

The tensions concern the Fiasp PumpCart and NovoRapid PumpCart cartridges with a dosage of 100 units/mL, which are "specifically compatible with the mylife YpsoPump insulin pump from the manufacturer Ypsomed," the French Agency for the Safety of Medicines (ANSM) stated in a press release.

The supply problems are linked to "an increase in sales of insulin cartridges, combined with the laboratory's limited production capacity, which temporarily prevents it from meeting demand."

According to Novo Nordisk, supply shortages are expected until the end of 2025 for these injectable solutions used to treat diabetes in adults, adolescents, and children, the ANSM reports. To reserve supplies for patients already receiving treatment, Novo Nordisk has asked prescribers not to start new treatments with Fiasp or NovoRapid PumpCart until the cartridge supply difficulties are resolved.

On the same subject

Diabetes: type 1 or type 2, what are the differences?

Diabetes is a chronic disease characterized by excess blood sugar. Glucose levels are normally regulated in the body by insulin, produced by the pancreas and permanently present in the blood. This hormone prevents hyperglycemia in the blood and allows glucose to penetrate cells. When insulin is ineffective or produced in insufficient quantities, hyperglycemia occurs. Without proper management, hyperglycemia becomes chronic, which is called diabetes.